ReviewJournal of fungi (Basel, Switzerland)2023
Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections.
Review in Journal of fungi (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- IntracranialJournal of child neurology · 2025Pooled it
- Unveiling Mucorales infections: A cutting-edge longitudinal imaging approach for real-time infection and host-response monitoring inVirulence · 2026Article
- Infection metallomics of pulmonary mucormycosis: multi-omics study of siderophore secretion, neutrophil recruitment, and lipid remodeling in rat lungs.Analytical and bioanalytical chemistry · 2026Article
- Total fungal RNA extraction from complex solid- state fermentation products.Applied microbiology and biotechnology · 2026Article
- Pulmonary mucormycosis with endobronchial involvement due toMedical mycology case reports · 2026Article
- Cutaneous mucormycosis confirmed using aFrontiers in medicine · 2026Article
- Fatal Cutaneous Mucormycosis Initially Misdiagnosed as Necrotizing Fasciitis in an Uncontrolled Diabetic Patient: A Case Report Highlighting Diagnostic Delay.International medical case reports journal · 2026Article
- Fatal Pharyngeal Cellulitis Caused byInfection and drug resistance · 2026Article
- Mucorales PCR Testing in Respiratory and Biopsy Samples From Immunocompromised Patients With Invasive Pulmonary Aspergillosis and Other Mold Infections: Results From a Multicenter ECMM Study.Open forum infectious diseases · 2026Article
- Monoclonal Antibodies Can Aid in the Culture-Based Detection and Differentiation ofAntibodies (Basel, Switzerland) · 2025Article
- Characterization of the Spatiotemporal Localization of a Pan-Mucorales-Specific Antigen During Germination and Immunohistochemistry.The Journal of infectious diseases · 2025Article
- Disseminated rhino-orbital-cerebral mucormycosis in Philadelphia chromosome-positive mixed phenotype acute leukemia: a case report and literature review.Frontiers in medicine · 2025Article
- Diagnostic Utility of Bronchoalveolar Lavage Metagenomic Next-Generation Sequencing for Pulmonary Mucormycosis: A Single-Center Retrospective Cohort Study.Infection and drug resistance · 2025Article
- Invasive Mucormycosis in a Chronic Lymphocytic Leukemia Patient on Zanubrutinib: A Case Report.Infection and drug resistance · 2025Article
- Article
- A Seminested PCR Method for the Diagnosis of Invasive Fungal Infections in Combat Injured.Open forum infectious diseases · 2024Article
- Molecular mechanisms that govern infection and antifungal resistance in Mucorales.Microbiology and molecular biology reviews : MMBR · 2024Review
- From Spores to Solutions: A Comprehensive Narrative Review on Mucormycosis.Diagnostics (Basel, Switzerland) · 2024Review
- Navigating the fungal battlefield: cysteine-rich antifungal proteins and peptides from Eurotiales.Frontiers in fungal biology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis is an uncommon, yet deadly invasive fungal infection caused by the Mucorales moulds. These pathogens are a WHO-assigned high-priority pathogen group, as mucormycosis incidence is increasing, and there is unacceptably high mortality with current antifungal therapies. Current diagnostic methods have inadequate sensitivity and specificity and may have issues with accessibility or turnaround time. Patients with diabetes mellitus and immune compromise are predisposed to infection with these environmental fungi, but COVID-19 has established itself as a new risk factor. Mucorales also cause healthcare-associated outbreaks, and clusters associated with natural disasters have also been identified. Robust epidemiological surveillance into burden of disease, at-risk populations, and emerging pathogens is required. Emerging serological and molecular techniques may offer a faster route to diagnosis, while newly developed antifungal agents show promise in preliminary studies. Equitable access to these emerging diagnostic techniques and antifungal therapies will be key in identifying and treating mucormycosis, as delayed initiation of therapy is associated with higher mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.